Summary. The breast tumor microenvironment of primary and metastatic sites is a complex milieu of differing cell populations, consisting of tumor cells and the surrounding stroma. Despite recent progress in delineating the immune component of the stroma, the genomic expression landscape of the non-immune stroma (NIS) population and their role in mediating cancer progression and informing effective therapies are not well understood. Here we obtained 52 cell-sorted NIS and epithelial tissue samples across 37 patients from i) normal breast, ii) normal breast adjacent to primary tumor, iii) primary tumor, and iv) metastatic tumor sites. Deep RNA-seq revealed diverging gene expression profiles as the NIS evolves from normal to metastatic tumor tissue, with intra-patient normal-primary variation comparable to inter-patient variation. Significant expression changes between normal and adjacent normal tissue support the notion of a cancer field effect, but extended out to the NIS. Most differentially expressed proteincoding genes and lncRNAs were found to be associated with pattern formation, embryogenesis, and the epithelial-mesenchymal transition. We validated the protein expression changes of a novel candidate gene, C2orf88, by immunohistochemistry staining of representative tissues. Significant mutual information between epithelial ligand and NIS receptor gene expression, across primary and metastatic tissue, suggests a unidirectional model of molecular signaling between the two tissues. Furthermore, survival analyses of 827 luminal breast tumor samples demonstrated the predictive power of the NIS gene expression to inform clinical outcomes. Together, these results highlight the evolution of NIS gene expression in breast tumors and suggest novel therapeutic strategies targeting the microenvironment.
Introduction
Breast cancer is the second most prevalent type of cancer worldwide and accounts for nearly 25% of total cancer incidence in women [1] . Recent studies have highlighted the importance of the breast tumor microenvironment (TME) in mediating and regulating tumor progression with respect to the adaptive immune system and therapeutic intervention. TME contains not only cancer cells, but a significant fraction of non-cancer cells that collectively is termed stroma [2] .
Importantly, high tumor stroma percentage (TSP) is associated with worse clinical outcome [2] , including breast cancer [3] . Tumor stroma consists of multiple different cell types, including immune cells, cancer-associated fibroblasts, and endothelial cells. The non-immune stroma (NIS) is thought to play an important structural role in the tumor microenvironment, forming the connective tissues and regulating production of the extracellular matrix (ECM), while also providing functional support for tumor progression/regression via processes such as cell proliferation, immune evasion, angiogenesis, apoptosis, and metastasis promotion [4] [5] [6] . In the case of pancreatic tumors, dense NIS tissues have shown to be the main barrier for immune infiltration and have consequently become the biggest challenge in developing pancreatic cancer therapies [7] . However, the role of NIS in breast cancer is not well understood.
In this study, we hypothesized that changes in NIS gene activity track progression from normal breast tissue to primary tumor and metastatic tumor, reflecting functional molecular communication between cancer cells and their surrounding NIS. To test this, fresh primary and metastatic tumor samples from breast cancer patients were obtained and processed for RNA-seq analysis. In order to compare gene expression levels in noncancerous tissue, normal adjacent breast tissues from these patients and normal breast tissues from BRCA mutant (BRCA+) subjects undergoing prophylactic mastectomy were also collected. Live cells cultured from fresh tissue samples were sorted for NIS and epithelial/cancer cells followed by whole transcriptome bulk RNA-sequencing. A pseudoalignment method was used to map and quantify these transcripts onto a reference human genome. Prior to any genomic analyses, we performed rigorous computational quality control and batch correction to obviate technical artefacts in the RNA-seq data (see Methods).
Whole genome transcriptional patterns of NIS, when projected onto low dimensional representations, reveal a robust progression from normal to primary tumor to metastatic tumor sites. This observation suggests that, rather than acting as an inert structural background to the tumor, NIS dynamically interacts with the changing epithelial-derived cancer cells. Surprisingly, we observed that normal tissue adjacent to breast tumors have distinct expression profiles to noncancerous breast tissues from healthy patients -instead are closer to NIS from its adjacent primary tumor. Furthermore, NIS cells from primary tumors were transcriptionally distinct from metastatic tumors with significant changes in NIS gene activity. We investigated the Gene Ontology of significantly differentially expressed genes and found functional enrichment in pattern formation, embryogenesis, epithelial-mesenchymal transition (EMT), and immune response functions. Significant differentially expressed genes, exclusively expressed in NIS tissue, such as the C2orf88 gene, were found to be downregulated in brain and liver metastatic sites as confirmed via IHC antibody validation. Further, we elucidated the NIS-epithelial crosstalk via ligand-receptor interactions and identified stronger ligand signaling originating from cancerous epithelial cells rather than from NIS cells. Together, these results support the concept of a cancer field effect [8, 9] , whereby cancerous cells in the primary site exert their influence on the gene expression pattern of neighboring normal cells, as well as the crosstalk between NIS cells and cancer cells aiding in tumor progression
Results

Breast tissue samples and bulk RNA-seq
To investigate the transcriptional landscape of NIS and cancer cells, fresh breast tissue samples were obtained from patients at the City of Hope cancer center. Over a two year period, 79 samples from 52 patients were successfully acquired and analyzed in seven different batches. We classified the samples into four types: i) prophylactic normal breast tissue from women without breast cancer, ii) normal breast tissue ipsi-/contralateral to primary breast tumor, iii) primary tumor, and iv) metastatic tumor. By definition, prophylactic normal samples are tissues that were taken from tumor negative patients with BRCA mutations who have undergone a prophylactic mastectomy procedure. Ipsilateral normal samples were collected from macroscopically noncancerous tissue areas located adjacent to a primary tumor site and confirmed by a pathologist to be noncancerous. Contralateral samples were collected similarly to ipsilateral normal samples but from the opposite breast, which was prophylactically resected during the primary tumor surgery. Primary tumor samples were tumors growing at the primary breast site whereas metastatic samples were tumor tissues that metastasized from the primary tumor to different locations in the body, specifically brain, liver, lung, skin, and bone. In order to capture a representative coverage of every tissue, short-term (1 week) in vitro culturing procedures were implemented to expand the cells and isolate sufficient amounts of RNA. This step was essential due to the limited number of fibroblasts that could be isolated from each tissue sample.
We implemented a cell-sorting step, in order to isolate pure NIS cells that consisted primarily of cancer-associated fibroblasts (CAF) and endothelial cells from the tumor samples.
In a previous study, our laboratory [10] showed that NIS could be generally identified by high expression of CD44 but low expressions of EPCAM and CD45. Epithelial cells and cancer cells express high levels of EPCAM but low levels of CD44 and CD45. By combining these three markers, we sorted cells from each tissue into NIS cells (CD44+, EPCAM-, CD45-) and epithelial/cancer cells (EPCAM+, CD44-, CD45-) via flow cytometry. Different cell populations found in NIS and epithelial samples are confirmed by expression of several canonical markers (Fig. 1b) , such as epithelial (EPCAM, CDH1), immune (CD45, CD3E), and fibroblast-pericyteendothelial (FAP, RGS5, PECAM1).
To extract messenger RNA (mRNA) and long noncoding RNA (lncRNA) from the entire RNA content produced by the samples, we excluded all significant contaminations such as rRNA, tRNA, and miRNA using standard library preparation methods. Once we acquired high yields of mRNA and lncRNA, sequencing libraries were produced by cDNA generation, fragmentation, size selection, PCR amplification, and barcoding.
In order to sequence the libraries, each batch was sent to the Cold Spring Harbor Laboratory sequencing facility. Attachment of library-specific barcodes allowed for pooling of all libraries in the same batch and simultaneously sequencing on an Illumina NextSeq 500 machine to obtain the reads. The FastQC [11] software was used to review read sequencing quality and ensure that low quality sample libraries were excluded in the subsequent processes.
A schematic summary of the entire sample-processing pipeline is shown in Fig. 1a 
Transcriptional progression of NIS
Inference of gene expression from sequencing data was implemented using a robust pseudoalignment and quantification pipeline, Kallisto [12] . The reads were mapped onto gene isoforms included in the human genome reference annotated by ENSEMBL [13] . This pipeline is and reactive oxygen species [16, 17] .
In Figure 2a , the primary tumor NIS show significant expression changes compared to ipsi-/contralateral normal tissues. These results support the idea of interactions between NIS cells and epithelial cancer cells in a breast tumor leading to transcriptional modification [18] .
Furthermore, the landscape of metastatic samples indicates a wider radial spread across the principal components. Metastatic samples diverge from primary samples nonlinearly due to strong dependence on different metastatic sites. We observed a strong diverging pattern in NIS samples variance ( 
Differential expressions of exclusive NIS genes
Transcription changes of NIS samples were examined by running a differential analysis on the expression matrix. We applied a conservative approach, Sleuth [19] , by taking the gene expressions along with the uncertainties for linear modeling and statistical testing. During the analysis, we incorporated patient, condition, and batch information as variable inputs with the corresponding statistical noise. Differential genes were determined from Wald test results with qvalue less than 0.05.
Significant differences between prophylactic normal and primary NIS samples are shown by p-value distribution in Fig. 2h , which depicts some significant genes with p-value less than 0.05. There are approximately 80 differential genes (q-value<0.05) that signify the transcriptional change between the two conditions. Among others, extracellular matrix genes such as TNC [20] appear to be significantly downregulated. We also found immune related genes that are involved in inflammatory responses such as IL11, RN7SL1, SERPINB9, and ALOX5AP [21] [22] [23] [24] . Long noncoding and histone genes were also significantly modified from prophylactic normal to primary conditions. These results indicate signaling interactions of NIS cells with cancer and immune cells in the tumor microenvironment. Furthermore, the significant genes collectively suggest their involvements in pattern formation, tissue development, and embryogenesis.
Comparisons between primary and metastatic tumor NIS were similarly described by significant p-value peak shown in Fig. 2g . We identified 108 differentially expressed genes with q-values less than 0.05, which have no overlap with the differential genes from normal versus primary. Among them, we can find multiple HOX genes and STRIP2 that are important in developmental and morphogenesis [25, 26] . Many growth factors and extracellular genes revealed in the list such as PGF, FGFR2 and NOG are significant in metastatic processes [27] [28] [29] . We also found CD36 and CD14, which are genes relevant to certain CAF functions such as cell adhesion, collagen binding, and immune response [30, 31] . Some noncoding genes that are well-known cancer markers such as HOTAIR and HAGLR [32, 33] were downregulated in breast NIS progression. On the other hand, WNT5B may be related directly to oncogenesis through the WNT signaling pathway [34] . To summarize, we provide the complete list of differential genes in both comparisons and paired analysis in the supplementary material (Table 1, Table 2, and Table   3 ).
4. Putative interactions between epithelial/cancer cells and NIS cells
To infer putative crosstalk between cancer cells and NIS cells, the gene expression dataset was cross-referenced to known ligand-receptor pairs. Only genes that were previously identified as angiogenesis, and cancer stem cell generation were also identified (EPHA and EPHB with EFNB1) [37, 38] . Upregulation of these pairs points towards a putative interaction and necessary role between the NIS cells and cancer cells. The list of ligand-receptor pairs with significant NIS q-value less than 0.1 is provided in supplementary material (Table 4 and Table 5 ).
The role of p53 in tumor progression has been widely studied and accepted. Mutation and dysregulation of the corresponding TP53 as a tumor suppressor gene can alter several biological functions that are important in tumor growth such as cell cycle arrest, DNA repair, apoptosis, angiogenesis, and metastasis [39] . Among the genes involved in p53-induced metastasis and angiogenesis [40] , Thrombospondin-1 (THBS1/TSP1) is downregulated in metastatic epithelial/cancer and NIS samples as depicted in Fig. 3a . To understand the crosstalk between cancer and NIS, we estimated the expression change of certain receptors and their ligands that emerged from p53 downstream pathways. An antiangiogenic receptor CD36 [41] is also found to be downregulated in metastatic samples, which suggests a possible signal from the epithelial/cancer ligand THBS1 towards the NIS receptor CD36 promoting metastasis.
Furthermore, opposite interactions are also indicated by the co-regulation between NIS ligand THBS1 and epithelial/cancer receptors ITGB3 and LRP1. The loss of cell adhesion caused by low expression of ITGB3 may drive cancer cells to detach [42] and metastasize from the primary site.
Together, these results signify the importance of cancer-NIS crosstalk in the progression of breast tumor.
Another way to approximate the interaction between NIS and epithelial/cancer cells is to quantify the mutual information between ligand and receptor pairs, which were listed in a previous study [43] . Mutual information, representing the strength of association for ligand/receptor pairs, was calculated from the t-test significant (p-value<0.1) expression changes between primary and metastatic conditions (see Methods). The advantage of using mutual information rather than any correlation coefficients is its ability to measure association in nonlinear and non-monotonic relationships [44] . We calculated the joint probability by counting the number of ligand-receptor pairs where the primary-metastatic expression changes increased or decreased. In Fig. 3b , we show the mutual information values in bits (corrected for finite number of samples) for random pairs of genes, NIS ligands/epithelial receptors, epithelial ligands/NIS receptors, and overall ligands/receptors. We found that there is a significant increase in the epithelial ligands/NIS receptors mutual information at about 0.021 bits. This is relatively high compared to random and NIS ligands/epithelial receptors which were close to zero. This discrepancy indicates a tendency towards uni-directional communication from epithelial/cancer ligands towards NIS receptors as the tumor progresses from primary to metastatic. Consequently, this supports the interaction between cancer cells and NIS as a part of EMT mechanism and the concept of cancer field effect. The list of ligand-receptor pairs with significant p-value less than 0.1 from primary to metastatic is provided in supplementary material (Table 6 and Table 7 ). 
C2orf88 expression predicts patient survival
To analyze specific NIS progression in a tumor, we filtered the differential gene expressions with a conditional threshold. The estimation of transcriptional noise becomes very relevant when distinguishing expression that is genuinely caused by active transcriptions. Based on the work by Wagner et al [45] , we implemented a threshold value of 2 tpm, which represents the baseline for background/noise transcription. Among the differential genes, we prioritized exclusive NIS genes with an average NIS expression above 2 tpm in at least one tissue condition, but lower than 2 tpm for epithelial samples in every tissue condition.
We investigated the functional role of a novel candidate NIS gene in our list of significant genes, namely C2orf88. The function of this protein-coding gene is largely unknown in cancer and only reported to be involved in protein kinase A binding and cell-cell interactions [46] . A previous study identified low expression of C2orf88 in tumor tissue compared to normal breast tissue using a cDNA microarray assay [47] . This study focused exclusively on the bulk 
IHC validates C2orf88 expression levels and NIS heterogeneity
Based on the differential and survival analysis results, we further validated the expression of
C2orf88, which has shown to be a good candidate for identifying NIS progression in tumors. To investigate C2orf88 expression change in tumors, we examined the intensity and population of cells that were stained with the antibody in luminal breast tumor tissues. In Fig. 4c , we see 
Discussion
The role of stroma in the progression of breast cancer remains a subject of ongoing research. 
Materials and Methods
Tissue and culturing
Deep RNA sequencing
Libraries were pooled with equal moles based on qubit mass measurements and expected fragment length. The libraries were sequenced on NextSeq 500 using a 75-cycle v2 SBS kit.
There was a 5% PhiX used as a control sample and the sequencing was done as a single-end 76 length with an index read. Reads were demultiplexed by barcode via the bcl2fastq2 tool.
Data and source code availablity
The raw sequence fastq data have been deposited in Sequence Read Archive (SRA) repository with accession code: SRP157590. The source code written in R for the bulk RNA-Seq analyses are available on https://github.com/AtwalLab/BulkRNAseq
Pseudoalignment and quantification
The RNA-seq sequence reads were pseudoaligned to coding and long noncoding regions in ENSEMBL Human genome (GRCh38 rel85) using an open-source package, Kallisto. The gene expression was quantified by "kallisto quant" with option attachments as follows: single end reads, first read reverse, bias correction, seed 42, fragment length 200 ± 20 bp, and bootstraps 100, and number of threads 4.
Principal component analysis and plotting was performed with the R function, "prcomp", and package, ggbiplot. Expression divergences were calculated by the cumulative sum of the i-th PC eigenvalues (e i ) that correspond to the variance, as follows:
The eigenvalues correspond to the variance of the samples in principal components space.
Differential analysis with batch correction and heatmap clustering
Differentially expressed genes were estimated using an open-source package Sleuth. We fit the 
Mutual information and survival analysis
The mutual information (I), in bits, between ligands expression change, L, and their associated receptors R expression change from primary to metastatic was calculated as: 
